DBV Technologies is making a comeback after making headway for its peanut allergy treatment in Europe.
Here are 20 biotechnology and pharmaceutical stocks that have been given big analyst upside targets for 2020.
DBV Tech shares jumped on Thursday after the firm announced positive topline results from its late-stage study in children with a peanut allergy.
Thursday's top analyst upgrades, downgrades and initiations included AMD, Amex, Apache, Coca-Cola, Ford, GM, Goldman Sachs, Lyft, Snap, Starbucks and Tesla.
DBV Technologies shares dipped on Monday after the firm announced an update from the FDA. Although it was a positive update for the company, this appears to be a case of “sell the news.”
DBV Tech shares shot up on Thursday after the company announced the submission of paperwork to the FDA for Viaskin Peanut for the treatment of peanut-allergic children.
Stocks were indicated to open marginally higher on Monday after gains of about 0.4% for the Dow and S&P 500 last week. This summer Monday is not seeing any vast amounts of new news rattling the...
DBV Technologies shares made a handy gain on Thursday after the company announced that it would be making some changes in its senior leadership ahead of its anticipated resubmission of its Viaskin...
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study be...
Weatherford Intertational, Eldorado Gold, DBV Technologies, and Kinder Morgan all posted new 52-week lows Monday.
The tale of two biotechs appears to be playing out between Aimmune Therapeutics and DBV Technologies, not just for the companies but between analysts as well.
The top analyst upgrades, downgrades and other research calls from Monday include Biogen, Equifax, Foot Locker, General Electric, NVIDIA, Rio Tinto and Roku.
DBV Technologies has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering